SCHEMBL5859286

SCHEMBL5859286

CCC(CC)NC(=O)c1cc(C2=C(C)C(=O)C(OC)=C(OC)C2=O)cc(C)c1-c1ccncc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 3/20 0.38
TAS1R1 Q7RTX1 3/20 0.38
TAS1R2 Q8TE23 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.35
PTK2 Q05397 1/20 0.35
HTT P42858 2/20 0.35
ROCK1 Q13464 11/20 0.34
ROCK2 O75116 7/20 0.34
PRKACA P17612 5/20 0.33
GSK3B P49841 5/20 0.33
PRKG1 Q13976 5/20 0.33
CLK4 Q9HAZ1 5/20 0.33
MAPK1 P28482 4/20 0.33
GSK3A P49840 4/20 0.33
RPS6KA3 P51812 4/20 0.33
PRKX P51817 4/20 0.33
RPS6KB1 P23443 3/20 0.33
CDK2 P24941 3/20 0.33
AKT1 P31749 3/20 0.33
AKT2 P31751 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5859860 0.82 IKBKB (0.37) AURKB
SCHEMBL5859140 0.82 CNR1 (0.45) ROCK1ROCK2CNR2
SCHEMBL5859281 0.81 CYP3A4 (0.48) SMN1; SMN2ALDH1A1CYP3A4
SCHEMBL6655451 0.80 CNR1 (0.48) HTTROCK1ROCK2ALDH1A1CNR2
SCHEMBL5859873 0.79 CNR1 (0.50) SMN1; SMN2HTTROCK1ROCK2ALDH1A1
SCHEMBL5860337 0.79 APOB (0.44)
SCHEMBL5862246 0.76 CYP2C9 (0.41) HTTALDH1A1CYP2C9
SCHEMBL5859258 0.74 ALDH1A1 (0.40) SMN1; SMN2HTTMAPK1ALDH1A1
SCHEMBL5859051 0.74 CYP46A1 (0.39) TAS1R3TAS1R1TAS1R2SMN1; SMN2PTK2
SCHEMBL5859208 0.73 PDE4B (0.43) HTTALDH1A1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7122543-B2 Substituted benzoic acid derivatives having NF-κB inhibiting action DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2006-10-17 US disclosed
EP-1437339-A1 SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-KAPPA B INHIBITING ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-07-14 EP disclosed
US-20040039061-A1 Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity DAIICHI ASUBIO PHARMA CO., LTD. (JP) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039061-A1 Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity NFKBIA, NFKB2, IKBKB TAS1R3 4332/4885TAS1R1 4038/4885TAS1R2 4058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.